Issues lobbied + lobbyists (4)
MAN — Manufacturing
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Lobbyists:- GIL ROTH — covered position: not applicable
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
PHA — Pharmacy
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Lobbyists:- GIL ROTH — covered position: not applicable
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE
TAR — Tariff (miscellaneous tariff bills)
Discussed response to Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients
HCR — Health Issues
Discussed issues related to User Fee reauthorization, onshoring/friendshoring initiatives, robustness of biopharmaceutical supply chains, drug shortages, workforce development, and potential impact of tariffs on domestic biopharmaceutical manufacturing.
Lobbyists:- GIL ROTH — covered position: not applicable
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE